CD6 and neoplasm: However, blocking CD6-ALCAM interaction with a neutralizing anti-ALCAM antibody did not significantly affect the viability of MDA-MB-231, NCI-H460 and HCT-116 tumor cell lines, and it only slightly decreased the viability of SKOV-3 (Figure 2A), suggesting that the enhanced effect on the killing activity of the PBMCs results from the blockade of CD6-CD318 interaction.